Need professional-grade analysis? Visit stockanalysis.com
$1.68B
N/A
59
N/A
Sionna Therapeutics, Inc. Common Stock (SION) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $43.54, down 3.76% from the previous close.
Over the past year, SION has traded between a low of $11.93 and a high of $45.24. The stock has gained 265.0% over this period. It is currently 265.0% above its 52-week low.
Sionna Therapeutics, Inc. Common Stock has a market capitalization of $1.68B.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Side-by-side comparison against top Healthcare peers.